ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more
ONWARD MEDICAL BV EO -12 (63E) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ONWARD MEDICAL BV EO -12 (63E) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ONWARD MEDICAL BV EO -12 - Net Assets Trend (None–None)
This chart illustrates how ONWARD MEDICAL BV EO -12's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONWARD MEDICAL BV EO -12 (None–None)
The table below shows the annual net assets of ONWARD MEDICAL BV EO -12 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ONWARD MEDICAL BV EO -12's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ONWARD MEDICAL BV EO -12 Competitors by Market Cap
The table below lists competitors of ONWARD MEDICAL BV EO -12 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chen Full International Co Ltd
TWO:8383
|
$101.07 Million |
|
CSB Bancorp Inc
PINK:CSBB
|
$101.12 Million |
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
$101.12 Million |
|
Zhejiang Yingfeng Technology Co Ltd
SHG:605055
|
$101.12 Million |
|
Suven Life Sciences Limited
NSE:SUVEN
|
$101.05 Million |
|
Steel Partners Holdings LP
NYSE:SPLP
|
$101.04 Million |
|
Omega Flex Inc
NASDAQ:OFLX
|
$101.01 Million |
|
Konya Cimento Sanayi AS
IS:KONYA
|
$100.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONWARD MEDICAL BV EO -12's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ONWARD MEDICAL BV EO -12's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ONWARD MEDICAL BV EO -12 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ONWARD MEDICAL BV EO -12's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONWARD MEDICAL BV EO -12 (63E) | €- | N/A | N/A | $101.06 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |